Ocugen Inc. stock OCGN rallied 16% in premarket trade Monday, after the biopharma company announced positive results in a trial of its COVID vaccine Covaxin. The Phase 2/3 trial involved 491 U.S. adult participants who receive two doses of Covaxin or placebo 28 days apart. Covaxin is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.
adult participants who receive two doses of Covaxin or placebo 28 days apart. Covaxin is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.
Pdr_US 🫡